How to Inject Retatrutide

Retatrutide is administered as a once-weekly subcutaneous injection — the same route used by Mounjaro (tirzepatide) and Wegovy (semaglutide). In clinical trials, it is delivered as a pre-filled, ready-to-use injection that does not require reconstitution.

Since retatrutide is not yet FDA-approved, there are no official prescribing instructions. The information below is based on clinical trial protocols and Eli Lilly's existing injectable drug platforms.

Injection Basics

Detail	Information
Route	Subcutaneous (into fatty tissue under the skin)
Frequency	Once weekly, on the same day each week
Device	Pre-filled pen (expected to use Lilly's KwikPen platform, same as Mounjaro)
Reconstitution	Not required — pre-filled and ready to use
Dose range	1–12 mg (titrated upward over weeks)

Injection Sites

Three subcutaneous injection sites are standard:

Abdomen — the most commonly preferred site. Inject at least 2 inches (two finger-widths) away from the belly button. Offers consistent absorption and easy self-access.
Front/outer thigh — halfway between knee and hip, on the outer front area. Reliable absorption and easy to reach.
Upper arm (back of arm) — may require assistance for self-injection. Some patients report feeling the needle less here.

Site Rotation

Rotate your injection site each week. Move at least 1 inch from the previous spot and alternate sides of the body. Consistent rotation prevents lipodystrophy (lumps under the skin), irritation, and inconsistent absorption.

Dose Titration Schedule

Retatrutide follows the same "start low, go slow" approach as other GLP-1 drugs. Phase 2 trial protocols used gradual dose escalation to minimize gastrointestinal side effects:

Week Range	Weekly Dose	Notes
Weeks 1–4	2–4 mg	Starting dose — minimizes nausea and GI upset
Weeks 5–8	4–8 mg	Intermediate step — weight loss effects begin, GI symptoms may peak
Weeks 9–12	8 mg	Therapeutic dose with significant weight loss
Weeks 13+	8–12 mg	Maintenance dose — 12 mg showed greatest weight loss (~29%)

The final commercial titration schedule may differ. Your doctor will determine the appropriate dose escalation based on how you respond and tolerate each dose level.

Step-by-Step Injection Process

Based on GLP-1 injectable pen standards (Mounjaro/Zepbound use a similar platform):

Wash hands thoroughly with soap and water
Remove pen from refrigerator approximately 30 minutes before injection — room-temperature medication is more comfortable
Inspect the solution — it should be clear and colorless. Do not use if cloudy, discolored, or containing particles
Choose your injection site — avoid bruised, scarred, or tender areas
Clean the area with an alcohol swab and let it air-dry
Prepare the pen — remove the cap, attach needle if applicable, prime by dialing until a drop appears at the needle tip
Pinch the skin to create a fold of tissue at the injection site
Insert the needle at a 90-degree angle (straight in) for most people. Use a 45-degree angle for leaner areas
Inject slowly — push the plunger or button steadily
Hold in place for 5–10 seconds to ensure the full dose is delivered
Remove the needle smoothly and apply light pressure with a cotton ball (do not rub)
Dispose of the needle in a sharps container immediately
Record the injection site and date to track your rotation

Storage

Condition	Instructions
Unopened (unused)	Refrigerate at 2–8°C (36–46°F). Do not freeze.
In use (opened)	Room temperature (up to 30°C / 86°F) for up to 28 days
Before injection	Remove from fridge ~30 minutes before use
Travel	Cool bag with ice packs, below 30°C, for up to 4 weeks
Do not	Freeze, shake vigorously, or expose to direct sunlight/heat

Gastrointestinal (Most Common)

GI side effects are dose-dependent and typically peak during dose escalation:

Nausea — most frequent, especially when moving to a higher dose
Vomiting — usually mild to moderate
Diarrhea
Constipation
Decreased appetite — this is partially the intended therapeutic effect

Most GI symptoms are mild to moderate and tend to diminish within the first month at each dose level.

Injection Site Reactions

Mild redness, swelling, or itching (usually resolves within a day)
Occasional bruising
Small bump that fades within minutes to hours

Proper site rotation and room-temperature injection minimize these reactions.

How Retatrutide Injection Compares

	Retatrutide	Tirzepatide (Mounjaro)	Semaglutide (Wegovy)
Frequency	Once weekly	Once weekly	Once weekly
Device	Pre-filled pen (expected)	KwikPen	FlexTouch pen
Dose range	1–12 mg	2.5–15 mg	0.25–2.4 mg
Injection sites	Abdomen, thigh, upper arm	Abdomen, thigh, upper arm	Abdomen, thigh, upper arm
Titration	Start low, go slow	Start low, go slow	Start low, go slow
Manufacturer	Eli Lilly	Eli Lilly	Novo Nordisk

If you are already using Mounjaro or Zepbound, the injection process for retatrutide will feel nearly identical — same manufacturer, same type of pen, same injection sites and technique.

Frequently Asked Questions

Is retatrutide a pill or injection?

Injection only. Retatrutide is a peptide that must be injected subcutaneously. There is no oral formulation available or in development. See Retatrutide Pill vs Injection.

How often do you inject retatrutide?

Once per week, on the same day each week. You can inject at any time of day — there are no food or fasting requirements.

Does the injection hurt?

Most patients describe GLP-1 pen injections as a brief pinch. The needles are very thin (typically 31-32 gauge). Letting the pen reach room temperature before injecting and rotating sites consistently minimizes discomfort.

Can I inject retatrutide myself?

Yes. GLP-1 pen injectors are designed for self-administration at home. The abdomen and thigh are the easiest sites for self-injection. Upper arm injections may require help from another person.

What happens if I miss a dose?

Clinical trial protocols for GLP-1 drugs generally advise: if you are within a few days of your scheduled dose, take it as soon as possible. If your next scheduled dose is within 2-3 days, skip the missed dose and resume your regular schedule. Do not double up. The exact guidance for retatrutide will be specified upon FDA approval.

Sources

Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972.
Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. DOI: 10.1016/S0140-6736(23)01053-X.
NowPatient. (2025). How to Inject Retatrutide. Link.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the FDA. The injection instructions above are based on clinical trial protocols and standard GLP-1 pen administration — final prescribing information will be published upon regulatory approval.

Do not self-administer any investigational drug. If you are interested in retatrutide, talk to your doctor about clinical trial enrollment.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.

Sources